University of Texas-MD Anderson Cancer Center: Ipilimumab and Nivolumab Immunotherapy Combination Produces High Response Rate in Metastatic Bladder Cancer
HOUSTON, Texas, May 20 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release:
An immunotherapy combination with a higher dose of ipilimumab produced a 38 percent overall response rate for patients with metastatic bladder cancer in a clinical trial led by investigators at The University of Texas MD Anderson Cancer Center that examined single-agent nivolumab and two combinations of the immune checkpoint inhibitors.
P . . .
An immunotherapy combination with a higher dose of ipilimumab produced a 38 percent overall response rate for patients with metastatic bladder cancer in a clinical trial led by investigators at The University of Texas MD Anderson Cancer Center that examined single-agent nivolumab and two combinations of the immune checkpoint inhibitors.
P . . .